Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC-Reference-Cited by-同舟云学术

Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC

Published:2014-02-27 Issue:1 Volume:11 Page:4-14
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Michael Michael¹,White Shane C²,Abdi Ehtesham³⁴,Nott Louise⁵,Clingan Phillip⁶,Zimet Allan⁷,Button Peter⁸,Gregory Daniel⁹,Solomon Benjamin¹⁰,Dobrovic Alexander¹⁰,Do Hongdo¹⁰,Clarke Stephen¹¹

Affiliation:

1. Division of Cancer Medicine; Peter MacCallum Cancer Centre; Melbourne Victoria Australia

2. Austin Health; Heidelberg Victoria Australia

3. The Tweed Hospital; Tweed Heads New South Wales Australia

4. Griffith University; Southport Queensland Australia

5. Royal Hobart Hospital; Hobart Tasmania Australia

6. Southern Medical Day Care Centre; Wollongong New South Wales Australia

7. Epworth Hospital; Richmond Victoria Australia

8. Infopeople, Pty Limited; Dee Why New South Wales Australia

9. Roche Products, Pty. Limited; Dee Why New South Wales Australia

10. Peter MacCallum Institute of Cancer Research; Melbourne Victoria Australia

11. Concord Repatriation General Hospital; Concord New South Wales Australia

Funder

Roche Products Pty Limited (Australia)

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12178/fullpdf

Reference50 articles.

1. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers;Gullick;Br Med Bull,1991

2. Molecular markers help characterize neuroendocrine lung tumors;Rusch;Ann Thorac Surg,1996

3. The role of amphiregulin in breast cancer;Salomon;Breast Cancer Res Treat,1995

4. Epidermal growth factor receptors in non-small cell lung cancer;Veale;Br J Cancer,1987

5. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells;Lei;Anticancer Res,1999

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer;Chemico-Biological Interactions;2022-01

2. Physicochemical characterization of Novel Particulate Delivery Systems for Antitumor/metastatic Therapeutics;Research Journal of Pharmacy and Technology;2021-09-14

3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Cochrane Database of Systematic Reviews;2021-03-18

4. Validation of stage groupings in the eighth edition of the tumor node metastasis classification for lung adenocarcinoma;Thoracic Cancer;2019-01-16

5. Systemic Therapy for Elderly Patients With Advanced Non–Small-Cell Lung Cancers;Journal of Clinical Oncology;2018-09-01